Liberate Bio has primate data and a new CMO. Can its in vivo CAR-M platform make the clinical leap?
Liberate Bio appoints Steven Bernstein as CMO as LIB820 advances toward a first human study in systemic sclerosis and in vivo CAR-M validation.
Pharma & Biotech